Nonetheless, given that there is preliminary evidence that EPO treatment may have clinical benefit in treatment of mild to moderate AD,88, 89 empirically guided approaches involving boosting EPO levels/oxygen supply to the brain via use of the currently available PHD inhibitors developed for treatment of anemia by the promotion of erythropoiesis may be of interest. The gene discussed is EPO; the disease is Alzheimer disease.